Drug Target Review

NOVEMBER 7, 2024

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Disease 52

Disease Immune Response Regulations Engineering 52

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Drug Target Review

JUNE 27, 2023

This ebook delves into the intricate world of cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and groundbreaking advancements in gene editing, featuring insightful interviews with renowned experts in the field.

Therapies 105

Therapies Immune Response Engineering Drugs 105

The Open Targets Blog

JANUARY 30, 2025

  “Sam has an exceptional talent in software engineering, and his contributions reflect a deep understanding of both the technical and biological aspects required for bioinformatics tool development,” says Laura Luebbert, now a postdoctoral fellow in the Sabeti lab at the Broad Institute of MIT and Harvard and Harvard University.

Bioinformatics 76

Bioinformatics Immune Response RNA Packaging 76

Drug Target Review

AUGUST 11, 2023

1 The study reveals a novel bioinformatic approach and tool that holds the potential to empower researchers in designing vaccines capable of inducing a stronger immune response. By selecting specific segments of proteins that elicit robust immune reactions, these vaccines could offer enhanced protection against diseases.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

Drug Target Review

NOVEMBER 11, 2024

This is partly because cancer cells are shrewd and often develop ways to evade immune detection. An important puzzle to solve is how to mount a good immune response in types of cancer with poor T-cell infiltration, or deficiencies in T-cell priming, and associated unresponsiveness to established immunotherapies.

Immune Response 52

Immune Response Treatment International Doctors 52

PLOS: DNA Science

FEBRUARY 8, 2024

The molecular tools of CRISPR were borrowed and developed from the natural immune response of bacteria to viruses – bacteriophages – that infect them. A recent paper in BioDesign Research , CRISPR-Cas-Based Engineering of Probiotics , from investigators at several Chinese research institutions, contributed to the report.

Immune Response 95

Immune Response DNA Engineering Virus 95

Drug Target Review

JANUARY 2, 2024

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses.

RNA 128

RNA Immune Response Therapies Disease 128

Broad Institute

JULY 11, 2024

Treatment with mIDH1 blockers unearths these remnants, triggering an immune response against the tumor cells. This immune response relies on the expression of a gene called cGAS , which produces part of a protein that detects retroviruses.

Treatment 72

Treatment Immune Response Drugs Virus 72

Drug Target Review

SEPTEMBER 11, 2023

This sugar-coated mucin binding to checkpoint receptors signals that the cancer cell poses no threat, consequently blocking the immune response. Tender elaborated that these results in immune cells ignoring the cancer rather than eliminating it, as they normally would.

Immune Response 116

Immune Response Research Virus Engineering 116

Drug Target Review

OCTOBER 16, 2023

2D cell models are often engineered to over-express the target of interest and so lack its temporal behaviour in its native or disease state. This is particularly pertinent in immune-based cell therapies like CAR-T, where animals do not mimic the human immune response.

Disease 122

Disease Immune Response Cell Biology Treatment 122

The Pharma Data

DECEMBER 17, 2020

Merck will select cancer targets and harness Janux’s proprietary Tumor Activated T Cell Engager (TRACTr) technology to engineer novel, T cell engager drug candidates. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response.

Immune Response 52

Immune Response Pharmacokinetics Engineering Licensing 52

Drug Target Review

DECEMBER 13, 2023

The genes unique to the severe long COVID patients were found to be associated with immune pathways such as myeloid differentiation, macrophage foam cells and lipid signalling pathways. She is a computational biologist with a background in bioprocess engineering and biotechnology.

Bioinformatics 145

Bioinformatics Disease Regulations Immune Response 145

Broad Institute

OCTOBER 4, 2023

Researchers from the Tumor Immunotherapy Discovery Engine ( TIDE ) at the Broad Institute of MIT and Harvard, AbbVie, and Calico Life Sciences report that the molecule simultaneously makes tumors more sensitive to immune attack and boosts the activity of immune cells to fight tumors in mice.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. About Novavax. Novavax, Inc.?(Nasdaq: Novavax Forward Looking Statements.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

Drug Target Review

JUNE 9, 2023

Genentech is responsible for engineering adaptive-discovered TCRs into T cells and manufacturing the T cell therapy product candidate. An antigen is a protein that can induce an immune response in the body. What types of diseases or conditions were targeted in the pre-clinical research phase?

Treatment 105

Treatment Packaging Clinical Research Therapies 105

The Pharma Data

NOVEMBER 22, 2020

The Agreement extends an existing relationship between the companies and gives Pandion the option to use standard phage display or mammalian display as the engines for the discovery of next generation antibodies.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

Drug Target Review

FEBRUARY 28, 2024

These include engineering the cells to express cytokines that promote their maturation and/or differentiation, and engineering drug-resistant γδ T cells that can be combined with chemotherapies, which stress cancer cells but would otherwise also deplete the T-cell population. References Fichtner A, Ravens S, Prinz I.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

APRIL 8, 2021

Early clinical results are consistent with preclinical studies and suggest THOR-707 (SAR444245) may promote an anti-tumor immune response without alpha-mediated side effects, both alone and in combination with anti-PD-1. Kenilworth, NJ, USA (known as MSD outside the U.S. About THOR-707 (SAR444245).

Immune Response 52

Immune Response Engineering Treatment Trials 52

PerkinElmer

MAY 6, 2022

One approach currently being explored involves stimulating innate immune response pathways. For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses.

Immune Response 52

Immune Response DNA Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

JUNE 1, 2022

Blocking an immune response-related enzyme holds promise in preventing or treating severe COVID-19 symptoms by reducing inflammation, tissue injury and blood clots in the lungs, new research in mice suggests. Previous research has shown that caspase 11 in mice has many of the same immune-response functions as caspase 4 in humans.

Immune Response 52

Immune Response Virus Engineering Disease 52

The Pharma Data

NOVEMBER 9, 2020

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.?Novavax?is

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

AUGUST 15, 2021

Melody Swartz, Jeffrey Hubbell and colleagues had previously developed a vaccine delivery tool called polymersomes – self-assembling, spherical nanoparticles that can encapsulate antigens and adjuvants (helper molecules that boost the immune response) and then release them inside immune cells.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

Drug Target Review

FEBRUARY 7, 2024

We had built a machine learning classifier that has been trained to identify amino acid sequences that have the potential to mimic ‘host defense peptides’ from the human innate immune system. Such peptides play a critical role in the machinery for amplifying innate immune responses.

RNA 69

RNA Virus Immune Response Engineering 69

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.?Novavax?is

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52

The Pharma Data

JANUARY 12, 2021

“The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors.

Therapies 52

Therapies Immune Response Research Clinical Development 52

The Pharma Data

OCTOBER 21, 2020

“We are particularly excited to advance on our goal to exploit the therapeutic potential of our first in class engineered CAR ?? We believe that ADI-001 offers the opportunity for on demand treatment, selective tumor targeting, innate and adaptive anti-tumor immune response, and durable activity in patients. About Adicet.

FDA 40

FDA Immune Response Clinical Trials Engineering 40

The Pharma Data

JANUARY 17, 2021

One consideration in using syngeneic models is that some drug candidates can cause a negative immune response not seen in humans. Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. This can prevent researchers from determining therapeutic efficacy in a preclinical study.

Immune Response 40

Immune Response Pharmacokinetics Engineering Licensing 40

The Pharma Data

JANUARY 6, 2021

ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. .” For further information please contact: ImaginAb Ian Wilson Email: info@imaginab.com Phone: +1 310 645 1211. About ImaginAb. ImaginAb Inc.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JANUARY 22, 2021

iosBio has claimed the OraPro platform enables oral delivery of thermally-stable, viral vector vaccines, which are engineered to withstand temperatures of up to 50°C. Novavax’s vaccine is a recombinant protein vaccine adjuvanted with Novavax’s nanoparticle technology, Matrix-M, which enhances immune response in recipients.

Vaccine 52

Vaccine Immune Response Government RNA 52

Drug Target Review

JANUARY 9, 2024

Using human cells is advantageous as bots could be built from a patient’s own cells to perform therapeutic work without initiating an immune response or needing immunosuppressants, drugs prescribed to prevent rejection of transplanted tissues and organs which are also used in the treatment of autoimmune disorders.

Laboratories 59

Laboratories Immune Response Science DNA 59

The Pharma Data

JUNE 25, 2021

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

OCTOBER 27, 2020

Be Bio plans to use their $52 million Series A to precisely engineer B cells to treat a range of diseases. Primmune’s early data shows the potential for PRTX007 to drive the natural innate immune response to combat systemic diseases. . said of B cells’ potential. The company’s $27.4

Small Molecule 52

Small Molecule Immune Response Clinical Development Therapies 52